BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 17962436)

  • 21. Absence of BRAF and NRAS mutations in uveal melanoma.
    Cruz F; Rubin BP; Wilson D; Town A; Schroeder A; Haley A; Bainbridge T; Heinrich MC; Corless CL
    Cancer Res; 2003 Sep; 63(18):5761-6. PubMed ID: 14522897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAF mutation detection and identification by cycling temperature capillary electrophoresis.
    Hinselwood DC; Abrahamsen TW; Ekstrøm PO
    Electrophoresis; 2005 Jun; 26(13):2553-61. PubMed ID: 15948220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absence of exon 15 BRAF germline mutations in familial melanoma.
    Lang J; Boxer M; MacKie R
    Hum Mutat; 2003 Mar; 21(3):327-30. PubMed ID: 12619120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region.
    Amanuel B; Grieu F; Kular J; Millward M; Iacopetta B
    Pathology; 2012 Jun; 44(4):357-9. PubMed ID: 22614711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
    Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
    J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAFV600E detection in melanoma is highly improved by COLD-PCR.
    Pinzani P; Santucci C; Mancini I; Simi L; Salvianti F; Pratesi N; Massi D; De Giorgi V; Pazzagli M; Orlando C
    Clin Chim Acta; 2011 May; 412(11-12):901-5. PubMed ID: 21262211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas.
    Sviatoha V; Tani E; Ghaderi M; Kleina R; Skoog L
    Anticancer Res; 2010 Sep; 30(9):3267-72. PubMed ID: 20944096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analysis of BRAF mutation and extracellular regulated protein kinases activation in nasal mucosa melanomas].
    Li HY; Zhou L; Tian J; Cong N
    Zhonghua Yi Xue Za Zhi; 2010 Dec; 90(48):3399-402. PubMed ID: 21223812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction.
    Turner DJ; Zirvi MA; Barany F; Elenitsas R; Seykora J
    J Cutan Pathol; 2005 May; 32(5):334-9. PubMed ID: 15811117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic Background of Iris Melanomas and Iris Melanocytic Tumors of Uncertain Malignant Potential.
    van Poppelen NM; Vaarwater J; Mudhar HS; Sisley K; Rennie IG; Rundle P; Brands T; van den Bosch QCC; Mensink HW; de Klein A; Kiliç E; Verdijk RM
    Ophthalmology; 2018 Jun; 125(6):904-912. PubMed ID: 29371009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
    Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
    Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis.
    Wu J; Rosenbaum E; Begum S; Westra WH
    Am J Dermatopathol; 2007 Dec; 29(6):534-7. PubMed ID: 18032947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
    Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
    Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer.
    Xing M
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):263-6. PubMed ID: 16117812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hotspot mutations of BRAF gene are not associated with pediatric solid neoplasms.
    Miao J; Kusafuka T; Fukuzawa M
    Oncol Rep; 2004 Dec; 12(6):1269-72. PubMed ID: 15547749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.
    Lee JH; Choi JW; Kim YS
    Br J Dermatol; 2011 Apr; 164(4):776-84. PubMed ID: 21166657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
    Griewank KG; Westekemper H; Murali R; Mach M; Schilling B; Wiesner T; Schimming T; Livingstone E; Sucker A; Grabellus F; Metz C; Süsskind D; Hillen U; Speicher MR; Woodman SE; Steuhl KP; Schadendorf D
    Clin Cancer Res; 2013 Jun; 19(12):3143-52. PubMed ID: 23633454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of BRAF mutation in primary uveal melanoma.
    Cohen Y; Goldenberg-Cohen N; Parrella P; Chowers I; Merbs SL; Pe'er J; Sidransky D
    Invest Ophthalmol Vis Sci; 2003 Jul; 44(7):2876-8. PubMed ID: 12824225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis.
    Kim KH; Suh KS; Kang DW; Kang DY
    Pathol Int; 2005 Sep; 55(9):540-5. PubMed ID: 16143028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma.
    Lin KL; Wang OC; Zhang XH; Dai XX; Hu XQ; Qu JM
    Ann Surg Oncol; 2010 Dec; 17(12):3294-300. PubMed ID: 20953721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.